To identify better cells for the treatment of diabetic critical limb ischemia (CLI) and foot ulcer in a pilot trial.
Under ordinary treatment, the limbs of 41 type 2 diabetic patients with bilateral CLI and foot ulcer were injected intramuscularly with bone marrow mesenchymal stem cells (BMMSCs), bone marrow-derived mononuclear cells (BMMNCs), or normal saline (NS).
The ulcer healing rate of the BMMSC group was significantly higher than that of BMMNCs at 6 weeks after injection (P = 0.022), and reached 100% 4 weeks earlier than BMMNC group. After 24 weeks of follow-up, the improvements in limb perfusion induced by the BMMSCs transplantation were more significant than those by BMMNCs in terms of painless walking time (P = 0.040), ankle-brachial index (ABI) (P = 0.017), transcutaneous oxygen pressure (TcO2) (P = 0.001), and magnetic resonance angiography (MRA) analysis (P = 0.018). There was no significant difference between the groups in terms of pain relief and amputation and there was no serious adverse events related to both cell injections.
BMMSCs therapy may be better tolerated and more effective than BMMNCs for increasing lower limb perfusion and promoting foot ulcer healing in diabetic patients with CLI.
Abbreviations:CLI (critical limb ischemia), PAD (peripheral arterial disease), BMMSCs (bone marrow mesenchymal stem cells), BMMNCs (bone marrow-derived mononuclear cells), NS (normal saline), ABI (ankle-brachial index), TcO2 (transcutaneous oxygen pressure), MRA (magnetic resonance angiography)
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Diabetes Research and Clinical Practice
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- The market in diabetes.Diabetologia. 2006; 49: 247-252
- The use of automated data to identify complications and comorbidities of diabetes: a validation study.J Clin Epidemiol. 1999; 52: 199-207
- Lower-extremity amputation in diabetes. The independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers.Diabetes Care. 1999; 22: 1029-1035
- Incidence of lower-limb amputation in the diabetic and nondiabetic general population a 10-year population-based cohort study of initial unilateral and contralateral amputations and reamputations.Diabetes Care. 2009; 32: 275-280
- Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome.Diabetes Care. 2001; 24: 1433-1437
- Vascular involvement in diabetic subjects with ischemic foot ulcer: a new morphologic categorization of disease severity.Eur J Vasc Endovas Surg. 2007; 33: 453-460
- Basic concepts to novel therapies: a review of the diabetic foot.Int J Low Extrem Wounds. 2010; 9: 90-102
- Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines.Circulation. 2001; 104: 1046
- Bone marrow mononuclear stem cells: potential in the treatment of myocardial infarction.Stem Cells Cloning: Adv Appl. 2009; 2: 11-19
- Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia.Cardiovasc Res. 2005; 66: 543-551
- Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion.Eur J Cardio-Thoracic Surg. 2006; 30: 353-361
- Intravenous infusion of immortalized human mesenchymal stm cells protects against injury in a cerebral ischemia model in adult rat.Exp Neurol. 2006; 199: 56-66
- Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model.Ann Thorac Surg. 2003; 75: 204-209
- Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model.Circulation. 2005; 111: 150-156
- Local delivery of marrow derived stromal cells augments collateral perfusion through paracrine mechanisms.Circulation. 2004; 109: 1543-1549
- Multilineage potential of adult human mesenchymal stem cells.Science. 1999; 284: 143-147
- Bone marrow stromal cells and bone marrow-derived mononuclear cells: which are suitable as cell source of transplantation for mice infarct brain?.Neuropathology. 2010; 30: 113-122
- Mesenchymal stem cells provide better results than hematopoietic precursors for the treatment of myocardial infarction.J Am Coll Cardiol. 2010; 55: 2244-2253
- Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats.Diabetes. 2008; 57: 3099-3107
- Treatment with bone marrow-derived stromal cells accelerates wound healing in diabetic rats.Int Wound J. 2008; 5: 453-463
- Impairment in ischemia-induced neovascularization in diabetes bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment.Am J Pathol. 2004; 164: 457-466
- Aging and diabetes impair the neovascular potential of adipose-derived stromal cells.Plast Reconstr Surg. 2009; 123: 475-485
- Locally applied mononuclear bone marrow cells restore angiogenesis and promote wound healing in a type 2 diabetic patient.Exp Clin Endocrinol Diabetes. 2005; 113: 538-540
- Autologous serum for isolation and expansion of human mesenchymal stem cells for clinical use.Exp Hematol. 2004; 32: 1212-1225
- Combination stem cell therapy for the treatment of severe limb ischemia: safety and efficacy analysis.Angiology. 2010; 61: 551-556
- Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial.Lancet. 2002; 360: 427-435
- Standard-protocol moving-table magnetic resonance angiography for planning of interventional procedures in patients with peripheral vascular occlusive disease.Clin Imaging. 2006; 30: 382-387
- Assessment of critical limb ischemia in patients with diabetes: comparison of MR angiography and digital subtraction angiography.Am J Roentgnol. 2005; 185: 1641-1650
- Human mesenchymal stem cells: from basic biology to clinical applications.Gene Therapy. 2008; 15: 109-116
- Treatment of severe acute graftversus-host disease with third party haplo identical mesenchymal stem cells.Lancet. 2004; 363: 1439-1441
- Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta.Nat Med. 1999; 5: 309-313
- Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study.Biol Blood Marrow Transplant. 2010;
- A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.J Am Coll Cardiol. 2009; 54: 2277-2286
- Bone marrow-derived mononuclear cell therapy induces distal angiogenesis after local injection in critical leg ischemia.Mod Pathol. 2008; 21: 837-846
- Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis.Stem Cells. 2007; 25: 2648-2659
- Enhanced wound-healing quality with bone marrow mesenchymal stem cells autografting after skin injury.Wound Repair Regen. 2006; 14: 325-335
Published online: January 10, 2011
Accepted: December 6, 2010
Received in revised form: October 19, 2010
Received: September 10, 2010
© 2010 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.